Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L BTC

NCT04066491 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

309

Enrollment

INDUSTRY

Sponsor class

Stopped Based on a review of data conducted by the Independent Data Monitoring Committee (IDMC), Sponsor decided to discontinue this study as the study was unlikely to achieve the primary objective of overall survival.

Conditions

Biliary Tract Cancer
Cholangiocarcinoma
Gallbladder Cancer

Interventions

DRUG: M7824
DRUG: Placebo
DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

EMD Serono Research & Development Institute, Inc.

Collaborators

[object Object]